AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Net revenue rose 58% YoY to $53.0M and the company swung to $35.7M net income from a $38.5M loss, driven by a mix shift toward excise-tax-free Israel and other-country flower sales that lifted gross margin to 54% from 43%.
Biggest Revenue Drivers
Cannabis flower$39.2M+57% YoY
Higher cannabis flower sales in Israel and other countries (Germany), which carry no excise taxes, and higher flower sales in Canada
Cannabis extracts$13.8M+65% YoY
Higher extract sales in the Canadian market
Biggest Revenue Drivers
Total revenue: $53.0M+58% YoY
Cannabis flower$39.2M+57% YoY
Higher cannabis flower sales in Israel and other countries (Germany), which carry no excise taxes, and higher flower sales in Canada
Cannabis extracts$13.8M+65% YoY
Higher extract sales in the Canadian market
Other$19K-73% YoY
Largest Expense Items
Cost of sales$24.2M+28% YoY
Higher sales volumes in the period
General and administrative$10.8M+3% YoY
Higher transaction costs related to the pending CanAdelaar acquisition and higher professional fees, partially offset by recovery of excise tax stamp penalties and lower anti-dumping and restatement litigation costs
Sales and marketing$6.8M+27% YoY
Higher trade marketing expenses and higher salaries and benefits
Research and development$1.2M+31% YoY
Increased testing, clinical study and other product development activity, plus higher salaries and benefits
Margins: Gross margin expanded to 54% from 43% a year ago, driven by higher average sales prices from a mix shift toward Israel and other excise-tax-free countries plus higher sales volumes spreading fixed overhead costs.
Watch Items from the Filing
Two major customers accounted for 44% of net revenue before excise taxes in Q2 2026, and 36% of accounts receivable was concentrated with two customers as of June 30, 2026 (up from 16% with one customer at year-end 2025).
Israel's Trade Levies Commissioner initiated a new anti-dumping investigation on August 5, 2026 alleging a ~125% prima facie dumping margin on Canadian cannabis imports, after terminating a prior probe on procedural grounds in July 2026.
Board renewed the share repurchase program for up to $50.0M (expiring May 2027); the company already repurchased $16.1M of shares in Q2 2026 and $32.9M year-to-date.
Proposed $10 million settlement of the 2019 restatement shareholder class action received preliminary court approval on August 4, 2026, though one Ontario plaintiff intends to oppose final approval.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
Martens ChristopherGeneral ManagerGrant or award · Oct 16, 2026
Garnick Murray RDirectorGrant or award · Aug 6, 2026
Adler Jason MarcDirectorGrant or award · Aug 6, 2026
Rudyk James DanielDirectorGrant or award · Aug 6, 2026
Kenost Jared MatthewReporting ownerGrant or award · May 12, 2026
Buggy ShannonReporting ownerShares withheld for tax or exercise price · May 12, 2026
Wagner AdamReporting ownerOption exercise · May 12, 2026
Doucet Terrence Gregory JosephReporting ownerShares withheld for tax or exercise price · May 12, 2026
Weigensberg AryeReporting ownerOption exercise · May 10, 2026
Shlimak AnnaReporting ownerShares withheld for tax or exercise price · Mar 19, 2026
About Cronos Group Inc. (CRON): stock profile, AI score and financials
Cronos Group Inc. (CRON) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CRON at 67.6/100 on a composite quality score built from its SEC filings, placing it at rank #360 of 2,925 stocks — the top 25% of the AI-ranked universe. CRON scores in the top quartile across profitability (96.4), revenue growth (89.2), free cash flow (81.8). Areas of concern include institutional flow (21.0) and revenue scale (22.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Cronos Group Inc. reports quarterly revenue of $53.0M, net income of $32.1M, an operating margin of 14.0%. Top institutional holders of CRON by reported 13-F value include D. E. Shaw, Chescapmanager, Toroso Investments, based on the most recent SEC filings. CRON trades on the Nasdaq exchange and files with the SEC under CIK 1656472. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRON daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cronos Group Inc. directly from SEC EDGAR.